DAA combinations used in the treatment of recently acquired and chronic HCV infection
| Product | Components | Administration | Duration of treatment | Most common adverse effects | ||
| NS5A inhibitor | Protease inhibitor | Polymerase inhibitor | ||||
| Pan-genotypic (G1–6) drug combinations | ||||||
| Epclusa | Velpatasvir 100 mg | – | Sofosbuvir 400 mg | 1 tablet once daily | 12 weeks | Headache Fatigue Gastrointestinal symptoms (nausea, diarrhoea) |
| Maviret | Pibrentasvir 40 mg | Glecaprevir 100 mg | – | 3 tablets once daily | 8 weeks 12 weeks (if treatment experienced and cirrhotic) | |
| Genotype-specific (G1 or G4) drug combinations | ||||||
| Harvoni | Ledipasvir 90 mg | – | Sofosbuvir 400 mg | 1 tablet once daily | 8–12 weeks | |
| Zepatier | Elbasvir 50 mg | Grazoprevir 100 mg | – | 1 tablet once daily | 12 weeks | |
| Retreatment after first-line DAA failure | ||||||
| Vosevi | Velpatasvir 100 mg | Voxilaprevir 100 mg | Sofosbuvir 400 mg | 1 tablet once daily | 12 weeks | |
DAA, direct acting antiviral.